Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions

The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This include...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacokinetics 2004, Vol.43 (1), p.1-15
Hauptverfasser: BAPTISTA, Trino, NG YING KIN, N. M. K, BEAULIEU, Serge
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 15
container_issue 1
container_start_page 1
container_title Clinical pharmacokinetics
container_volume 43
creator BAPTISTA, Trino
NG YING KIN, N. M. K
BEAULIEU, Serge
description The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.
doi_str_mv 10.2165/00003088-200443010-00001
format Article
fullrecord <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A199858512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A199858512</galeid><sourcerecordid>A199858512</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-3a5a61229702f8f4cc4b67de120ab6a2b722afea7324055d537eef49c7fc65263</originalsourceid><addsrcrecordid>eNptkU1L5TAUhsPgMF51_sIQEJd1cvLV1p2IHwPCbHRdTtNEM7bNJUkX99-b672jCCaLwJvnOYS8hFBg5xy0-s3KEqxpKs6YlIIBq7YRfCMrgLqtoOX6gKyYAF6pVotDcpTSv0I0RfhBDkHWoJhsVuTlIVrMk50zDY7mZ0snm7EPozd08CkvscfZ2EQNLskOtN9QnLNfp415DnkLxeUpXdCbYJZEw0zXIZdhHse3G-rnbCOa7MOcTsh3h2OyP_fnMXm8uX64uqvu_97-ubq8r4xQIlcCFWrgvK0Zd42Txshe14MFzrDXyPuac3QWa8ElU2pQorbWydbUzmjFtTgmp7u5Tzjazs8u5PKEySfTXULbNqpRwAt1_gVV9mAnb8JsnS_5J6HZCSaGlKJ13Tr6CeOmA9Zta-n-19K91_IWQVF_7dT10k92-BD3PRTgbA9gMji6WD7dpw9OSS1ASPEKKq-VMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>BAPTISTA, Trino ; NG YING KIN, N. M. K ; BEAULIEU, Serge</creator><creatorcontrib>BAPTISTA, Trino ; NG YING KIN, N. M. K ; BEAULIEU, Serge</creatorcontrib><description>The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-200443010-00001</identifier><identifier>PMID: 14715048</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Antipsychotic Agents - adverse effects ; Biological and medical sciences ; Drug Interactions ; Drug toxicity and drugs side effects treatment ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - pharmacokinetics ; Hypoglycemic Agents - therapeutic use ; Hypolipidemic Agents - adverse effects ; Hypolipidemic Agents - pharmacokinetics ; Hypolipidemic Agents - therapeutic use ; Medical sciences ; Metabolic Syndrome - chemically induced ; Metabolic Syndrome - drug therapy ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology</subject><ispartof>Clinical pharmacokinetics, 2004, Vol.43 (1), p.1-15</ispartof><rights>2004 INIST-CNRS</rights><rights>COPYRIGHT 2004 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c353t-3a5a61229702f8f4cc4b67de120ab6a2b722afea7324055d537eef49c7fc65263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15463134$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14715048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BAPTISTA, Trino</creatorcontrib><creatorcontrib>NG YING KIN, N. M. K</creatorcontrib><creatorcontrib>BEAULIEU, Serge</creatorcontrib><title>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Drug Interactions</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Hypolipidemic Agents - adverse effects</subject><subject>Hypolipidemic Agents - pharmacokinetics</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Metabolic Syndrome - chemically induced</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1L5TAUhsPgMF51_sIQEJd1cvLV1p2IHwPCbHRdTtNEM7bNJUkX99-b672jCCaLwJvnOYS8hFBg5xy0-s3KEqxpKs6YlIIBq7YRfCMrgLqtoOX6gKyYAF6pVotDcpTSv0I0RfhBDkHWoJhsVuTlIVrMk50zDY7mZ0snm7EPozd08CkvscfZ2EQNLskOtN9QnLNfp415DnkLxeUpXdCbYJZEw0zXIZdhHse3G-rnbCOa7MOcTsh3h2OyP_fnMXm8uX64uqvu_97-ubq8r4xQIlcCFWrgvK0Zd42Txshe14MFzrDXyPuac3QWa8ElU2pQorbWydbUzmjFtTgmp7u5Tzjazs8u5PKEySfTXULbNqpRwAt1_gVV9mAnb8JsnS_5J6HZCSaGlKJ13Tr6CeOmA9Zta-n-19K91_IWQVF_7dT10k92-BD3PRTgbA9gMji6WD7dpw9OSS1ASPEKKq-VMQ</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>BAPTISTA, Trino</creator><creator>NG YING KIN, N. M. K</creator><creator>BEAULIEU, Serge</creator><general>Adis international</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2004</creationdate><title>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</title><author>BAPTISTA, Trino ; NG YING KIN, N. M. K ; BEAULIEU, Serge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-3a5a61229702f8f4cc4b67de120ab6a2b722afea7324055d537eef49c7fc65263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Drug Interactions</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Hypolipidemic Agents - adverse effects</topic><topic>Hypolipidemic Agents - pharmacokinetics</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Metabolic Syndrome - chemically induced</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BAPTISTA, Trino</creatorcontrib><creatorcontrib>NG YING KIN, N. M. K</creatorcontrib><creatorcontrib>BEAULIEU, Serge</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BAPTISTA, Trino</au><au>NG YING KIN, N. M. K</au><au>BEAULIEU, Serge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>2004</date><risdate>2004</risdate><volume>43</volume><issue>1</issue><spage>1</spage><epage>15</epage><pages>1-15</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>14715048</pmid><doi>10.2165/00003088-200443010-00001</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0312-5963
ispartof Clinical pharmacokinetics, 2004, Vol.43 (1), p.1-15
issn 0312-5963
1179-1926
language eng
recordid cdi_gale_infotracmisc_A199858512
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Antipsychotic Agents - adverse effects
Biological and medical sciences
Drug Interactions
Drug toxicity and drugs side effects treatment
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - pharmacokinetics
Hypoglycemic Agents - therapeutic use
Hypolipidemic Agents - adverse effects
Hypolipidemic Agents - pharmacokinetics
Hypolipidemic Agents - therapeutic use
Medical sciences
Metabolic Syndrome - chemically induced
Metabolic Syndrome - drug therapy
Miscellaneous (drug allergy, mutagens, teratogens...)
Neuropharmacology
Pharmacology. Drug treatments
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
title Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T13%3A52%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20the%20metabolic%20disturbances%20caused%20by%20antipsychotic%20drugs:%20Focus%20on%20potential%20drug%20interactions&rft.jtitle=Clinical%20pharmacokinetics&rft.au=BAPTISTA,%20Trino&rft.date=2004&rft.volume=43&rft.issue=1&rft.spage=1&rft.epage=15&rft.pages=1-15&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-200443010-00001&rft_dat=%3Cgale_cross%3EA199858512%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14715048&rft_galeid=A199858512&rfr_iscdi=true